Citadel Advisors’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $168K | Sell |
20,000
-1,700
| -8% | -$17.9K | ﹤0.01% | 11588 |
|
|
2025
Q4 | $312K | Sell |
21,700
-21,200
| -49% | -$264K | ﹤0.01% | 10044 |
|
|
2025
Q3 | $414K | Buy |
42,900
+16,900
| +65% | +$149K | ﹤0.01% | 9579 |
|
|
2025
Q2 | $213K | Sell |
26,000
-8,300
| -24% | -$69.5K | ﹤0.01% | 10534 |
|
|
2025
Q1 | $245K | Buy |
34,300
+2,600
| +8% | +$19.3K | ﹤0.01% | 10030 |
|
|
2024
Q4 | $245K | Buy |
31,700
+16,000
| +102% | +$150K | ﹤0.01% | 10077 |
|
|
2024
Q3 | $165K | Buy |
15,700
+6,400
| +69% | +$78K | ﹤0.01% | 10441 |
|
|
2024
Q2 | $109K | Sell |
9,300
-800
| -8% | -$12.5K | ﹤0.01% | 10801 |
|
|
2024
Q1 | $213K | Sell |
10,100
-2,900
| -22% | -$51.6K | ﹤0.01% | 10185 |
|
|
2023
Q4 | $233K | Buy |
13,000
+1,500
| +13% | +$26.4K | ﹤0.01% | 9642 |
|
|
2023
Q3 | $189K | Buy |
11,500
+6,000
| +109% | +$109K | ﹤0.01% | 10000 |
|
|
2023
Q2 | $110K | Sell |
5,500
-1,700
| -24% | -$32.8K | ﹤0.01% | 10788 |
|
|
2023
Q1 | $136K | Buy |
7,200
+3,000
| +71% | +$66.4K | ﹤0.01% | 10795 |
|
|
2022
Q4 | $95.3K | Buy |
+4,200
| New | +$94.9K | ﹤0.01% | 11288 |
|
|
2022
Q3 | – | Sell |
-9,100
| Closed | -$225K | – | 13456 |
|
|
2022
Q2 | $225K | Sell |
9,100
-6,500
| -42% | -$162K | ﹤0.01% | 10454 |
|
|
2022
Q1 | $518K | Buy |
15,600
+7,500
| +93% | +$208K | ﹤0.01% | 9304 |
|
|
2021
Q4 | $265K | Sell |
8,100
-63,400
| -89% | -$2.16M | ﹤0.01% | 11204 |
|
|
2021
Q3 | $3M | Buy |
71,500
+60,500
| +550% | +$2.18M | ﹤0.01% | 5368 |
|
|
2021
Q2 | $427K | Sell |
11,000
-3,500
| -24% | -$125K | ﹤0.01% | 10408 |
|
|
2021
Q1 | $495K | Sell |
14,500
-11,900
| -45% | -$508K | ﹤0.01% | 9697 |
|
|
2020
Q4 | $1.2M | Buy |
26,400
+9,600
| +57% | +$335K | ﹤0.01% | 6411 |
|
|
2020
Q3 | $462K | Buy |
16,800
+2,700
| +19% | +$88K | ﹤0.01% | 7439 |
|
|
2020
Q2 | $519K | Sell |
14,100
-20,600
| -59% | -$768K | ﹤0.01% | 7006 |
|
|
2020
Q1 | $1.12M | Sell |
34,700
-29,700
| -46% | -$1.24M | ﹤0.01% | 5127 |
|
|
2019
Q4 | $2.64M | Buy |
64,400
+39,000
| +154% | +$1.54M | ﹤0.01% | 3987 |
|
|
2019
Q3 | $904K | Sell |
25,400
-5,700
| -18% | -$231K | ﹤0.01% | 5765 |
|
|
2019
Q2 | $1.6M | Sell |
31,100
-3,500
| -10% | -$175K | ﹤0.01% | 4906 |
|
|
2019
Q1 | $1.98M | Sell |
34,600
-4,200
| -11% | -$208K | ﹤0.01% | 4483 |
|
|
2018
Q4 | $1.63M | Buy |
38,800
+9,700
| +33% | +$569K | ﹤0.01% | 4484 |
|
|
2018
Q3 | $2.2M | Buy |
29,100
+17,800
| +158% | +$1.28M | ﹤0.01% | 4245 |
|
|
2018
Q2 | $811K | Buy |
11,300
+1,600
| +16% | +$76.4K | ﹤0.01% | 5565 |
|
|
2018
Q1 | $290K | Buy |
+9,700
| New | +$282K | ﹤0.01% | 6799 |
|
Other funds holding RGNX
RG
VCM
IHAM
Citadel Advisors's RGNX Position: Q1 2026 in Review
Citadel Advisors sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 46,641 shares — an estimated $490K sold.
Citadel Advisors first reported a position in RGNX in Q3 2015 and held it in 38 quarters. The position peaked at $37.1M in Q3 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.
- Citadel Advisors reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 46,641 Regenxbio shares in Q1 2026, an estimated $490K.
- Citadel Advisors first reported a position in Regenxbio in Q3 2015 and held it in 38 quarters.
- Citadel Advisors's Regenxbio position peaked at $37.1M in Q3 2018.
- 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.